Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recommended statin therapy. METHODS: We conducted a randomized, controlled trial involving patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both. Patients had to have an LDL cholesterol level of at least 70 mg per deciliter while they were receiving maximally tolerated statin therapy with or without additional lipid-lowering therapy. (Maximally tolerated statin therapy was defined as the highest intensity statin regimen that a patient was able to maintain, as determined by the investigator.) Patients were randomly assigned in a 2:1 ratio to receive bempedoic acid or placebo. The primary end point was safety, and the principal secondary end point (principal efficacy end point) was the percentage change in the LDL cholesterol level at week 12 of 52 weeks. RESULTS: The trial involved 2230 patients, of whom 1488 were assigned to receive bempedoic acid and 742 to receive placebo. The mean (±SD) LDL cholesterol level at baseline was 103.2±29.4 mg per deciliter. The incidence of adverse events (1167 of 1487 patients [78.5%] in the bempedoic acid group and 584 of 742 [78.7%] in the placebo group) and serious adverse events (216 patients [14.5%] and 104 [14.0%], respectively) did not differ substantially between the two groups during the intervention period, but the incidence of adverse events leading to discontinuation of the regimen was higher in the bempedoic acid group than in the placebo group (162 patients [10.9%] vs. 53 [7.1%]), as was the incidence of gout (18 patients [1.2%] vs. 2 [0.3%]). At week 12, bempedoic acid reduced the mean LDL cholesterol level by 19.2 mg per deciliter, representing a change of -16.5% from baseline (difference vs. placebo in change from baseline, -18.1 percentage points; 95% confidence interval, -20.0 to -16.1; P<0.001). Safety and efficacy findings were consistent, regardless of the intensity of background statin therapy. CONCLUSIONS: In this 52-week trial, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of overall adverse events than placebo and led to significantly lower LDL cholesterol levels. (Funded by Esperion Therapeutics; CLEAR Harmony ClinicalTrials.gov number, NCT02666664.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CLEAR Harmony trial assessed bempedoic acid’s safety and efficacy in 2230 statin-treated patients with atherosclerosis or HeFH compared with placebo [130]. Relative to placebo, bempedoic acid reduced LDL-C by − 16%, non-HDL-C by − 13%, total cholesterol by − 11%, ApoB-100 by − 12% and hsCRP by − 22%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“The incidence of adverse events was similar across both interventional groups, yet a higher percentage discounted treatment with bempedoic acid than placebo (10.9% versus 7.1%). Gout was more frequently observed among patients treated with bempedoic acid (1.2% versus 0.3%).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“Safety findings in the real-world setting were generally aligned with those reported in RCTs and meta-analyses [[12], [13], [14], [15],17,18], although reporting was limited and inconsistently captured.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [12]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Enzymatic Determination of Total Serum Cholesterol
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,125
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
A peroxidase-coupled method for the colorimetric determination of serum triglycerides.
McGowan, M. W., Artiss, J. D., Strandbergh, D. R., & Zak, B. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.538 · Cited by 1,298
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Self-citationBallantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Self-citationMendelian Randomization Study of ACLY and Cardiovascular Disease
Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D. R., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., Di Angelantonio, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 342
Self-citation
Cited by
Items 501–600 of 807
Bempedoic Acid for Lipid Management in the Indian Population: An Expert Opinion
Hiremath, J., Mohan, J. C., Hazra, P., Sawhney, J. P. S., Mehta, A., Shetty, S., Oomman, A., Shah, M., Bantwal, G., Agarwal, R., et al. (2023) · Cureus · doi:10.7759/cureus.35395 · Cited by 5
“DOI 10.7759/cureus.35395 2 of 10 Studies Population Number and distribution of patients Study duration Intervention Mean % reduction in bempedoic acid group at 12 weeks in lipid parameters LDLC hsCRP Non- HDL- C Total cholesterol ApoB CLEAR Harmony [10] ASCVD and/or HeFH; taking maximally tolerated statin with or with…”
BackgroundMethodResultInfluentialBempedoic acid: what prospective uses?
Jacomelli, I., Monzo, L., Panattoni, G., Lanzillo, C., Rebecchi, M., & Calò, L. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad012 · Cited by 4
Yaseen, M. S., & Ali, N. A. K. M. (2022) · Cellular and Molecular Biology · doi:10.14715/cmb/2022.68.10.15 · Cited by 7
“This illustrates the greater beneficial effects of BA on total cholesterol levels and coincides with the results of other studies that reported a reduction in LDL-C serum levels was 15% greater by BA than by Statins (18).”
ResultThe Role of Lipid-Lowering Therapy in Post-Stroke Patients: Update and Recommendations
Avenatti, E., Avila, J. C., Heidari, B., Hagan, K., Taha, M. B., & Nasir, K. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01159-2 · Cited by 6
“…the treatment of adults with heterozygous familial hypercho-lesterolemia or established ASCVD who require additional lowering LDL-C based on the results of CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Harmony trial [27] and CLEAR Wisdom Randomized Clinical Trial [28].”
MethodThe year in cardiology: cardiovascular prevention. The year in cardiology 2019.
Ray, K. K., Laufs, U., Cosentino, F., Lobo, M. D., & Landmesser, U. (2020) · SA Heart · doi:10.24170/17-1-4022 · Cited by 5
Self-citationAn update on emerging drugs for the treatment of hypercholesterolemia
Nelson, A. J., Bubb, K. J., & Nicholls, S. J. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.2009801 · Cited by 5
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac123.29883001 · Cited by 4
A Newly Approved Cholesterol Drug Joins the Lipid-Lowering Arsenal: Bempedoic Acid
Furer, J., Popova, O., & Plakogiannis, R. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2020.08.022 · Cited by 5
Bempedoic Acid to Lower LDL Cholesterol — Safety and Efficacy
Giral, P. (2020) · New England Journal of Medicine · doi:10.1056/nejmc1908495 · Cited by 4
Serio, L., Paolucci, A., Carugno, M. E., Cappannari, S., Cecchini, A., Litterio, M., Pinto, R. D., & Ferri, C. (2025) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-025-00732-x · Cited by 3
“In contrast, the incidences of hyperuricemia and increased serum creatinine levels are higher in bempedoic acid compared to placebo-treated patients [10, 12 ].”
Rovera, C., Zoppo, A. D., Petralli, G., Moriconi, D., Rossi, C., Distaso, M., Brunetto, M. R., Ferrannini, E., Raggi, F., & Solini, A. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104373 · Cited by 3
Pavanello, C., Cincotto, G., Mombelli, G., Castiglione, S., Santolamazza, C., Calabresi, L., Sirtori, C., & Alberti, A. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.09.033 · Cited by 4
Hu, M., Gong, Z., Li, X., Xia, J., & Yin, C. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.10.076 · Cited by 3
Review of Lipid-Lowering Therapy in Women from Reproductive to Postmenopausal Years
Witting, C. S., Devareddy, A., & Rodríguez, F. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2305183 · Cited by 7
“Bempedoic acid, which inhibits cholesterol biosynthesis, has been shown to decrease LDL-C by around 17% [53,54].”
BackgroundZhu, X., Cui, S., Liu, X., Zhang, M., Xie, Z., Li, W., Li, J., Nan, F., Zhang, Y., Zhan, Y., et al. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116056 · Cited by 3
Metabolic basis of cardiac dysfunction in cancer patients
Figueiredo, J. C., Bhowmick, N. A., & Karlstaedt, A. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001118 · Cited by 3
The Role of Genetics in Advancing Cardiometabolic Drug Development
Abou-Karam, R., Cheng, F., Gady, S., & Fahed, A. C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01195-6 · Cited by 4
“Subsequently, bempedoic acid, an ATP citrate lyase inhibitor, showed LDL cholesterol reduction in clinical trials and became FDA approved [60].”
Shen, F., Chu, C., Chen, J., Kuo, C., Hsu, C., Lin, C., Sheen, Y., Su, S., Tien, K., Lu, C., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14222 · Cited by 4
“Studies have reported LDL-C reductions of 17 – 28% 57 – 60 .”
Nagamallika, G., & Jadav, A. (2024) · Asian Journal of Research in Chemistry · doi:10.52711/0974-4150.2024.00060 · Cited by 3
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention
Kamanu, C., & Karalis, D. G. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01283-1 · Cited by 6
“This distinct mechanism translates to a significantly lower risk of statin-associated muscle symptoms compared with statin therapy [ 9 , 28 ].”
Ogunniyi, K. E., Aghasili, C. C., Akinmoju, O. D., Olaiya, V. O., Abib, O. M., Odueke, A., Popoola, H. A., Onyenokwe, V., Onaolapo, D., Usman, A.-A. M., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00762-9 · Cited by 3
“For lower-risk patients or those averse to injections, bempedoic acid is supported by the CLEAR Harmony and CLEAR Wisdom trials [36, 37].”
MANAGEMENT OF PATIENTS WITH DYSLIPIDEMIA IN THE PRACTICE OF FAMILY MEDICINE
Seredyuk, N. M., Seredyuk, V., Деніна, Р. В., Zvonar, P. P., Bielinskyi, M. V., & Andriitsiv, Z. S. (2021) · Art of Medicine · doi:10.21802/artm.2021.3.19.69 · Cited by 3
van der Laarse, A., & Cobbaert, C. M. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.2022475 · Cited by 4
Seijas‐Amigo, J., Gayoso-Rey, M., Mauriz-Montero, M. J., Suárez‐Artime, P., Casas-Martínez, A., Dominguez-Guerra, M., González-Freire, L., Estany-Gestal, A., Codero-Fort, A., Rodríguez‐Mañero, M., et al. (2022) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2022.01.003 · Cited by 3
Bempedoic acid in patients with type 2 diabetes
Masson, W. M., Barbagelata, L., Lobo, M., & Nogueira, J. P. (2022) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2021.11.003 · Cited by 3
Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review
Hassen, L. J., Scarfone, S. R., & Milks, M. W. (2022) · Geriatrics · doi:10.3390/geriatrics7020038 · Cited by 5
“Bempedoic acid is a novel oral small molecule agent used to promote LDL-C reduction that functions as an ATP citrate lyase (ACL) inhibitor, thus reducing cholesterol biosynthesis upstream of HMG-CoA reductase [46].”
BackgroundThe pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 4
Self-citationLipidtherapie bei Patienten mit Diabetes mellitus
Parhofer, K. G., Birkenfeld, A. L., Krone, W., Lehrke, M., Marx, N., Merkel, M., Schütt, K. S., Zirlik, A., & Müller‐Wieland, D. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00905-5 · Cited by 4
“Inhaltliche Änderungen gegenüber der Vorjahresfassung Änderung 1: Bempedoinsäure als Alternative bei Statinintoleranz erwägen Begründung: Studien zeigen weniger Myopathie – allerdings bisher keine Endpunktstudien Stützende Quellenangabe: [14]”
Gergely, T. G., Brenner, G. B., Nagy, R. N., Sayour, N. V., Makkos, A., Kovácsházi, C., Tian, H., Schulz, R., Giricz, Z., Görbe, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021585 · Cited by 4
Luca, L. D., Riccio, C., Navazio, A., Valente, S., Cipriani, M., Corda, M., Nardo, A. D., Francese, G. M., Napoletano, C., Tizzani, E., et al. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad100 · Cited by 3
“38–40 The impact of bem-pedoic acid on CV events is being evaluated in the CLEAR OUTCOMES trial, which recently completed the enrolment of 14 014 patients intolerant to statins and high CV risk or known CV disease.”
MethodPark, J. K., Balarbar, N., & Agarwala, A. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01911-9 · Cited by 4
Bhandari, A., Oli, P. R., Shrestha, D. B., Dawadi, S., Pathak, B. D., Bhandari, M., Sedhai, Y. R., Basnet, B., Regmi, L., Singh, A., et al. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100116 · Cited by 3
Carpio-Tenorio, C. D., Llerena-Velastegui, J., Villacis‐Lopez, C., Placencia‐Silva, M., Santander-Fuentes, C., Benitez-Acosta, K., Sanahuja-Montiel, C., Dominguez-Gavilanes, D., Carrasco-Perez, P., & Calderon-Lopez, C. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102191 · Cited by 3
How Will Our Practice Change After the CLEAR Outcomes Trial?
Abrahams, T., Nelson, A. J., & Nicholls, S. J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01188-5 · Cited by 3
“The CLEAR Harmony [27] and Wisdom [28] studies evaluated the impact of bempedoic acid in patients treated with either high intensity (51”
BackgroundTranslational bioinformatics approach to combat cardiovascular disease and cancers
Shahjahan, Dey, J. K., & Dey, S. K. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.11.006 · Cited by 3
Ou, Z., Wang, F., Chen, Y., Liu, X., Ran, B., Yin, Y., & Cui, K. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07622-9 · Cited by 7
“More-over, the combination of ACL inhibitor with statin further reduced LDL-C levels compared with statin alone [24, 25].”
InfluentialLu, J., Li, G. H., Hu, J., & Wang, Z. (2025) · Communications Biology · doi:10.1038/s42003-025-07860-z · Cited by 4
“Given that ACLY inhibitors have been used in clinical trials to reduce LDL-C levels 26,64 , we investigated the effects of LDL-C on melanoma-associated proteins to validate the observed relationships between ACLY inhibition and the identi fi ed proteins.”
InfluentialBempedoinsäure – Wirkmechanismus und klinische Studien
Katzmann, J. L., & Laufs, U. (2020) · Aktuelle Kardiologie · doi:10.1055/a-1142-7957 · Cited by 3
“Phase-III-Studien mit mehr als 1000 Patienten: „ CLEAR Harmony “ und „ CLEAR Outcomes “ Die Nachbeobachtungsphase der großen randomisierten End-punktstudie „ CLEAR Outcomes “ läuft aktuell, Ergebnisse werden 2022 erwartet [15].”
BackgroundInfluentialLDL-cholesterol reduction in chronic kidney disease: options beyond statins
Goonasekera, M. A., Mafham, M. M., & Haynes, R. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000628 · Cited by 4
A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 4
▼Bempedoic acid: another cholesterol-lowering drug
(2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2022.000035 · Cited by 3
Familial hypercholesterolemia: current status of the problem, treatment, and prevention
Bliznyuk, S. А., Bubnova, M. G., & Владиславович, Е. М. (2020) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2020-2532 · Cited by 6
Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia
Schimmenti, C., Sucato, V., Manzone, E., Cancellieri, G., Mortillaro, F., Novo, G., Galassi, A. R., & Venturella, F. (2020) · Coronary Artery Disease · doi:10.1097/mca.0000000000000976 · Cited by 3
Bempedoic Acid: A New Avenue for the Treatment of Dyslipidemia
Smith, W., Cheng-Lai, A., & Nawarskas, J. J. (2021) · Cardiology in Review · doi:10.1097/crd.0000000000000401 · Cited by 3
Familial hypercholesterolaemia and emerging therapeutics
Farias, F. I., Kim, S. M., & Shapiro, M. D. (2023) · Heart · doi:10.1136/heartjnl-2022-321917 · Cited by 4
Bempedoic acid: Everything with a place and purpose
Westerink, J. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320929779 · Cited by 3
Yenilmez, B., Kelly, M., Zhang, G., Wetoska, N., Ilkayeva, O., Min, K., Rowland, L. A., DiMarzio, C., He, W., Raymond, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.21.485183 · Cited by 3
“In phase 3 clinical trials, bempedoic acid reduced the mean LDL cholesterol level by up to 30% (74) in patients with hypercholesterolemia and by around 18% in patients on statin medications (73) .”
BackgroundInfluentialStrategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments
Polychronopoulos, G., Papagiannis, A., & Τζιόμαλος, Κ. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2174524 · Cited by 4
“Novel agents that reduce LDL-C levels, including bempedoic acid and, in selected patients, evinacumab, might also be useful [25,26].”
BackgroundEvaluating the effect of bempedoic acid on kidney function: call for cautious implementation.
Groothof, D., & Bakker, S. J. (2024) · The Lancet Diabetes and Endocrinology · doi:10.1016/s2213-8587(24)00062-7 · Cited by 2
Pirillo, A., Casula, M., Baragetti, A., & Catapano, A. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00001-7 · Cited by 3
Self-citationMolecular diagnostics of familial hypercholesterolemia in Russia: yesterday, today and tomorrow
Zakharova, F. M., Мандельштам, М. Ю., Bogoslovskaya, T. Y., & Vasiliev, V. B. (2024) · Medical academic journal · doi:10.17816/maj630505 · Cited by 2
Wang, X., Liu, Y., Han, H., Ma, J., Tian, N., Zhu, R., Shi, X., Jin, J., & Zhou, H. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468868 · Cited by 2
“However, it has been suggested that very long-chain acyl-CoA synthetase 1, the activating enzyme of bempedoic acid, is not expressed in skeletal muscle, which will reduce the occurrence of muscle-related adverse reactions of this drug [16].”
In vivo effects of bempedoic acid on microdosed CYP probe drugs
Stoll, F., Amato, S., Burhenne, J., & Blank, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1544956 · Cited by 2
Guo, H., Wang, Q., Wang, Y., Dong, X., Wang, Z., Kang, H., & Cheng, S. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1524697 · Cited by 3
Klose, M., Weber, L., & Bachmann, H. S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331440 · Cited by 3
“Bempedoic acid is known to lower low-density lipoprotein cholesterol levels in humans by inhibiting ATP citrate lyase, a key enzyme in the cholesterol biosynthesis pathway that acts upstream of HMG-CoA reductase, the target of statins [19].”
Bempedoic Acid and the Uric Acid Paradox: Reflections on the Recent Meta-analysis
Bonanni, L., & Ferri, N. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07781-3 · Cited by 2
“Its efficacy has been shown in different contexts: ~ –21% as monotherapy in statin-intolerant patients [2], –17–18% when added to statins [4], and ~ –30–40% when combined with ezetimibe or PCSK9 inhibitors [2].”
Wang, Y., Wang, P., Xu, F., Zhou, H., Xie, X., Hou, T., Luo, F., Sun, Y., Liu, Y., Wang, J., et al. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106874 · Cited by 2
Masuda, D., Kajinami, K., Sakayoshi, N., Yokota, D., Nagamine, M., Isogai, Y., & Yamashita, S. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65947 · Cited by 3
“In the CLEAR Harmony trial, the change was 0.73 ± 1.11 mg/dL in the bempedoic acid group and −0.06 ± 0.87 mg/dL in the placebo group, suggesting that this effect may be attributable to the mechanism of action of bempedoic acid 12) .”
InfluentialBouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Matteucci, A., Fusco, S. A. D., Bonanni, M., Marino, G., Fedele, S., Nardi, F., & Colivicchi, F. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.02.018 · Cited by 6
Hyperuricemia risk in bempedoic acid-treated hyperlipidemic patients
Su, P., Tsai, D. H., Hsieh, M. H., Vairaperumal, T., Lai, E. C.-C., & Liu, P. Y. (2026) · Communications Medicine · doi:10.1038/s43856-026-01545-2 · Cited by 3
Alkayed, H. A., Rajesh, R., Shaikh, A., Martins, R., & Alrabadi, B. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.04.015 · Cited by 3
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Self-citationDyslipidaemias in cancer patients
Nazir, M. S., Cegla, J., Andrés, M. S., Ray, K. K., & Lyon, A. R. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag265 · Cited by 2
Self-citationRepurposing bempedoic acid as a histone deacetylase 6 inhibitor
Ediriweera, M. K., Rajan, P., & Cho, S. K. (2023) · International Journal of Epigenetics · doi:10.3892/ije.2023.15 · Cited by 2
Bempedoic acid a novel drug used for the treatment of Hyperlipidaemia: A Review
Shimpi, R., Barhate, S., & Jain, M. (2023) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2023.00013 · Cited by 2
Fang, F., Zhao, H., Wang, R., Chen, Q., Wang, Q.-Y., & Zhang, Q. (2023) · Materials · doi:10.3390/ma16134641 · Cited by 2
“, statins [11], bempedoic acid [12], inclisiran [13]) are the two most prevalent clinical interventions used to regulate the LDL levels.”
BackgroundHypercholesterinämie und kardiovaskuläres Risiko
Sinning, D., & Landmesser, U. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1932-6448 · Cited by 2
Sai Datri, A. (2023) · Current Trends in Biomedical Engineering & Biosciences · doi:10.19080/ctbeb.2023.21.556066 · Cited by 2
Nisar, S., Sohail, S., Fatima, S., Akhtar, M. T., Ahmad, M., Hanif, M. W., Khan, M., Mehmoodi, A., & Malik, J. (2024) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1313 · Cited by 3
OS TIPOS DE TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA E CONTROLE DOS TRIGLICERÍDEOS
Nogueira, D. R., Melo, G. C. D. C., Silva, I. D. A. C. E., Moreira, L. E. P., Pedrosa, M. D. S. B., Cardinali, M. D. P., Peron, P. L. V., & Piazzi, R. G. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p13 · Cited by 5
Efficacy and Safety of Bempedoic Acid as a Treatment Option for Hyperlipidemia: A Systematic Review
Sharif, M. H., Orakzai, A. A., Khaleeque, M., Raza, S. S., Khan, O. S., Jan, M. H., Ahmed, A., & Arsalan, M. (2024) · Advances in Clinical Medical Research and Healthcare Delivery · doi:10.53785/2769-2779.1198 · Cited by 1
Goyal, A., Shah, S., Dahal, K., Changez, M. I. K., Tariq, M. D., Zuhair, V., Shamim, U., Abbasi, H. Q., Shrestha, A. B., Sah, R., et al. (2024) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000302 · Cited by 3
“BA is a first-in-class, once-daily oral agent for the optimal treatment of hypercholesterolemia as an add-on as well as mono-therapy [11].”
Yasmin, F., Najeeb, H., Moeed, A., Ali, E., Umar, M., Ullah, I., Shah, N. P., & Alraies, M. C. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001715 · Cited by 3
Interplay of Metastasis, Cancer Stem Cells, and Energy Metabolism in Cancer Progression
Mal, A. (2025) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-025-00059-8 · Cited by 2
Management of Dyslipidemia in Chronic Kidney Disease
Vedamurthy, D., Sagheer, U., Patel, A., Singh, G., & Kalra, D. K. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00763-y · Cited by 3
“Bempedoic acid helps lower LDL-C by inhibiting ATP citrate lyase upstream of the site of action of statins in the cholesterol biosynthesis pathway [49].”
Benucci, M., Terenzi, R., Gobbi, F. L., Cassarà, E. A. M., Picchioni, T., Russo, E., Lari, B., Manfredi, M., & Infantino, M. G. (2025) · Antibodies · doi:10.3390/antib14030063 · Cited by 2
“Moreover, among the genetic risk factors, the MHC class II allele HLA-DRB111:01 has been strongly associated with a predisposition to anti-HMGCR-positive IMNM [11,12].”
Recent progress in anti-atherosclerosis strategies and prospective therapeutic targets
Wang, Z., He, X., Bai, H., Feng, D., Qu, Y., Zhang, Y., Lee, R. J., & Sun, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126122 · Cited by 4
Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis
Masson, W. M., Lobo, M., Cobo, A. L., & Molinero, G. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.06.001 · Cited by 5
2019 clinical trials in lipid lowering
Feldman, D. I., Pacor, J., Blumenthal, R. S., & Nasir, K. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000757 · Cited by 2
Pharmacological Management of Hyperlipidemia in Older Individuals
Tsu, L. V., Carroll, K. A., Kindler, K., & Early, N. K. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.284 · Cited by 2
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
Noh, S., Mai, K., Shaver, M., Yong, S., MOSTAGHIMI, M., Oh, G., & Radwan, M. M. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.12.011 · Cited by 3
Clinical strategies for reducing cholesterol levels
Lardinois, C. K., & Karr, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00027-4 · Cited by 2
High-Sensitivity C-Reactive Protein
Feldman, D. I., Blumenthal, R. S., & Gluckman, T. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_17 · Cited by 2
The Pathogenetic Basis of the Action of Bempedoic Acid
Petrosyan, A. S., Rud', R. S., Polyakov, P. P., Каде, А. Х., & Zanin, S. A. (2023) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2022-12-11 · Cited by 2
Safarova, M. S., Santos, R. D., & Moriarty, P. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00034-0 · Cited by 2
Korosoglou, G., Giesen, A., Geiss, E., & Stach, K. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1203832 · Cited by 2
Wang, X., Wen, D., Fang, M., You, C., & Ma, L. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2410286 · Cited by 2
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 4
An Industry Update in Therapeutics: What is the Latest news?
Reis, C. P. (2019) · Therapeutic Delivery · doi:10.4155/tde-2019-0026 · Cited by 2
Sabouret, P. F., Angoulvant, D., Pathak, A., Costa, F., Pezel, T., & Michos, E. D. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0627-8 · Cited by 3
The mega-importance of de novo lipogenesis in platelet production
Nazy, I., Arnold, D. M., & Steinberg, G. R. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00282-7 · Cited by 2
Working towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
Stimulus‐Responsive Nanoparticles for Therapeutic Stabilization of Atherosclerosis
Mehta, S., Ahamad, N., Dewani, M., Bhardwaj, P., & Banerjee, R. (2021) · Wiley eBooks · doi:10.1002/9783527832095.ch7 · Cited by 3
Bempedoic Acid, an Inhibitor of Cholesterol Biosynthesis, Reduces Cardiovascular Events
Jialal, I., & Olatunbosun, S. T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103463 · Cited by 2
Sadaf, S., Vasamsetti, S. B., Jamal, I., Johny, E., Kubra, K., Haque, S., Mannan, A. A. S. R., Razani, B., Chaparala, S., Okawa, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.10.681697 · Cited by 5
Systematic literature review on the real-world effectiveness and safety of bempedoic acid
Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100562 · Cited by 1
Management of Statin Intolerance
Bartłomiejczyk, M. A., Penson, P. E., & Banach, M. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_12 · Cited by 1
Drugs for lipid disorders, antiplatelet drugs and fibrinolytics
Waller, J. R. (2022) · Medicine · doi:10.1016/j.mpmed.2022.04.012 · Cited by 1
Larina, V. N., Головко, М. Г., Геннадьевич, Л. В., Mironovna, T. N., & Orlov, D. A. (2023) · Cardiosomatics · doi:10.17816/cs133705 · Cited by 2
“…[28]; CLEAR Harmony Trial ( n= 2230, пациенты с выраженным атеросклерозом и/или гетеро-зиготной семейной гиперлипидемией, период лечения 54 нед) [29]. https://doi.org/10.17816/CS133705 Безопасность терапии статинами весьма актуальна, посколь-ку настороженность врачей относительно возможных…”
Influential
Metadata
- Authors
- Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-14
- Volume
- 380
- Issue
- 11
- Pages
- 1022-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2922038538
- Cited by
- 807
- References
- 20
- Citations by year
- 2026: 77 · 2025: 87 · 2024: 114 · 2023: 143 · 2022: 116 · 2021: 107 · 2020: 107 · 2019: 53
- FWCI
- 91.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- bempedoic acid, LDL cholesterol lowering, ATP-citrate lyase inhibitor, hypercholesterolemia, atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, statin therapy, gout, adverse events, drug safety, lipid-lowering therapy, long-term treatment, gout risk, statin intolerance
- MeSH terms
- Aged, Apolipoproteins B, ATP Citrate (pro-S)-Lyase, C-Reactive Protein, Cholesterol, Dicarboxylic Acids, Drug Therapy, Combination, Fatty Acids, Female, Humans, Hypercholesterolemia, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Peptide Fragments, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.